UCIVIDY Trademark

Trademark Overview


On Tuesday, March 28, 2023, a trademark application was filed for UCIVIDY with the United States Patent and Trademark Office. The USPTO has given the UCIVIDY trademark a serial number of 97860535. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, March 17, 2025. This trademark is owned by Athira Pharma, Inc.. The UCIVIDY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical agents for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis
ucividy

General Information


Serial Number97860535
Word MarkUCIVIDY
Filing DateTuesday, March 28, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateMonday, March 17, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 8, 2025

Trademark Statements


Goods and ServicesPharmaceuticals for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis; pharmaceutical agents for use in the prevention and treatment of neurodegenerative, neurologic, neuropsychiatric and inflammatory disorders such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, neuropathy and neuropathic pain, stroke, depression, insomnia, schizophrenia, hearing loss and rheumatoid arthritis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 4, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAthira Pharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBothell, WA 98011

Trademark Events


Event DateEvent Description
Friday, March 31, 2023NEW APPLICATION ENTERED
Tuesday, April 4, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 21, 2023ASSIGNED TO EXAMINER
Thursday, January 18, 2024NON-FINAL ACTION WRITTEN
Thursday, January 18, 2024NON-FINAL ACTION E-MAILED
Thursday, January 18, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 26, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, January 26, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, July 15, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 15, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 15, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 16, 2024ASSIGNED TO EXAMINER
Friday, October 25, 2024ASSIGNED TO EXAMINER
Wednesday, December 4, 2024FINAL REFUSAL WRITTEN
Wednesday, December 4, 2024FINAL REFUSAL E-MAILED
Wednesday, December 4, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, March 3, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 3, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, March 3, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 11, 2025APPROVED FOR PUB - PRINCIPAL REGISTER